• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Buoyed by new data on hemophilia A gene therapy, BioMarin boosts enrollment in head-to-head...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   May 22, 2018 at 10:12: AM
via With its hemophilia A gene therapy poised to go through a pivotal program by the end of next year, BioMarin $BMRN is raising hopes for its success with a new batch of Phase I/II data for its valrox program (valoctocogene roxaparvovec/BMN 270).

article source
 




Top Bottom
Back
Quote